1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–73.
2. Bronchial asthma: World Health Organization factsheet.
http://www.who.int/mediacentre/factsheets/fs206/en
. Accessed 31 May 2018.
3. Kim H, Ellis AK, Fischer D, Noseworthy M, Olivenstein R, Chapman KR, et al. Asthma biomarkers in the age of biologics. Allergy Asthma Clin Immunol. 2017;13:48.
4. Albers FC, Müllerová H, Gunsoy NB, Shin JY, Nelsen LM, Bradford ES, et al. Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study. J Asthma. 2018;55(2):152–60.
5. Smith SG, Zhang S, Jayasundara K, Tacon C, Simidchiev A, Nadeau G, et al. Identification and description of severe asthma patients in a cross-sectional study (IDEAL): Canadian subject results. In: 2016 Canadian Society of Allergy and Clinical Immunology annual scientific meeting proceedings. Allergy Asthma Clin Immunol. 2017; 13(Suppl 1): 16.